Evidence map›Paper›PMID 21775642›Full record

Trial reportNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2011

The effects of an oral supplement enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients.

Dawn M Wiese, Bret A Lashner, Edith Lerner, Stephen J DeMichele, Douglas L Seidner

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2023
    Article
  4. Review
  5. Omega Fatty Acids and Inflammatory Bowel Diseases: An Overview.International journal of molecular sciences · 2019
    Review
  6. Avoidance of Fiber Is Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Dawn M WieseInternal Medicine, Vanderbilt University Medical Center, B-510 TVC, Box 396, Nashville, TN 37232-5283, USA. dawn.m.wiese@vanderbilt.edu
Bret A Lashner
Edith Lerner
Stephen J DeMichele
Douglas L Seidner
Vanderbilt University Medical Center · USCase Western Reserve University · USCleveland Clinic · USRoss Laboratories (United States) · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1RR024989
6 · The paper itself

Abstract

backgroundResearch in the treatment of Crohn's disease (CD) supports anti-inflammatory benefits of n-3 fatty acids from fish oil, prebiotics, and antioxidants. A nutritionally balanced inflammatory bowel disease nutrition formula (IBDNF) enriched with these compounds has the potential to improve nutrition status and disease activity in CD.

methodsThis is an open-label pilot study investigating the effects of IBDNF on nutrition status in CD patients. Twenty-eight patients with active CD on stable medication were asked to consume 16 oz of IBDNF/d for 4 months. Nutrition status was assessed with dual-energy X-ray absorptiometry scans and serum micronutrient levels. Disease activity and quality of life were measured using the Crohn's Disease Activity Index (CDAI) and the Inflammatory Bowel Disease Questionnaire (IBDQ).

resultsTwenty patients completed the final visit. After 4 months, there was a significant decrease in plasma phospholipid levels of arachidonic acid with increases in eicosapentaenoic acid (EPA) and docosahexaenoic acid. Ten patients had a final EPA concentration of >2%. There was improvement in fat-free and fat mass in patients with final EPA >2% (P = .014 and P = .05). Vitamin D (25-OH) levels improved in all patients (18.5-25.9 ng/mL, P < .001). Those with EPA >2% had significantly lower CDAI (116 ± 94.5 vs 261.8 ± 86.5; P = .005) and higher IBDQ (179.1 ± 26.6 vs 114.6 ± 35.9, P < .001) compared to those with EPA <2%.

conclusionsIBDNF has the potential to deposit fat-free and fat mass, improve vitamin D status, and improve quality of life in CD patients.

Indexed as

PrebioticsAdipose TissueAdministration, OralAdultAgedAntioxidantsArachidonic AcidBody Fluid CompartmentsCrohn DiseaseDietary FiberDietary SupplementsDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidFatty Acids, Omega-3Fatty Acids, Unsaturated25-hydroxyvitamin DAntioxidantsArachidonic AcidDietary FiberDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidFatty Acids, Omega-3Fatty Acids, UnsaturatedFish OilsPhospholipidsPrebioticsVitamin D

Identifiers

PMID21775642
PMCPMC4457393
OpenAlexW2167152727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.